bioAffinity Technologies, Inc. (BIAFW)
| Market Cap | 7.42M -14.4% |
| Revenue (ttm) | 5.66M -35.8% |
| Net Income | -15.88M |
| EPS | -5.86 |
| Shares Out | 4.49M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,645 |
| Open | 0.2001 |
| Previous Close | 0.2001 |
| Day's Range | 0.1800 - 0.2002 |
| 52-Week Range | 0.0525 - 0.8121 |
| Beta | -1.19 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 8, 2026 |
About BIAFW
bioAffinity Technologies, Inc. engages in developing non-invasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. The company operates through two segments: Diagnostic Research and Development; and Laboratory Services. The company offers CyPath lung which uses flow cytometry technology to detect and analyze cell populations in a person’s sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cance... [Read more]
News
BioAffinity says CyPath Lung test unit sales achieved monthly record in April
BioAffinity Technologies (BIAF) announced that unit sales for its CyPath Lung diagnostic test achieved a record high in a single month and increased nearly 300% in April 2026 compared to…
bioAffinity Technologies Reports Record Monthly CyPath® Lung Unit Sales and Significant Year-Over-Year Growth in April 2026
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #CyPathLung--bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on noninvasive diagnostics and early cancer detection, today a...
BioAffinity Technologies reports Q1 EPS (81c) vs. ($4.80) last year
Reports revenue $1.4M vs. $1.9M last year. “Our first quarter results demonstrate continued momentum for CyPath Lung in the marketplace. As more and more physicians adopt CyPath Lung and share…
bioAffinity Technologies Reports First Quarter 2026 Results and Expanding Adoption and Clinical Usage of CyPath® Lung
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #CyPathLung--bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection ...
bioAffinity Technologies Earnings release: Q1 2026
bioAffinity Technologies released its Q1 2026 earnings on May 8, 2026, summarizing the period's financial results.
bioAffinity Technologies Quarterly report: Q1 2026
bioAffinity Technologies has published its Q1 2026 quarterly earnings report on May 8, 2026.
BioAffinity Technologies files to sell 497,483 shares of common stock for holder
17:09 EDT BioAffinity Technologies (BIAF) files to sell 497,483 shares of common stock for holder
bioAffinity Technologies Registration statement: Registration filing
bioAffinity Technologies filed a registration statement on April 30, 2026, providing details about a securities offering with the SEC.
BioAffinity Technologies launches new study to expand use of CyPath lung tech
bioAffinity Technologies (BIAF) announced a pilot study with Brooke Army Medical Center, BAMC, to evaluate the Company’s proprietary tests under development to identify specific inflammatory biomarker...
bioAffinity Technologies Launches New Study To Expand Use of CyPath® Lung Technology for Asthma and COPD Diagnosis and Treatment
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #AI--bioAffinity Technologies announces study with Brooke Army Medical Center to evaluate new diagnostic tests to improve treatment for asthma and COPD.
BioAffinity Technologies releases clinical case on CyPath Lung
bioAffinity Technologies (BIAF) released a new clinical case study illustrating how CyPath Lung, the Company’s noninvasive sputum-based diagnostic test, helped determine next steps for a high-risk pat...
New Case Study: bioAffinity Technologies' CyPath® Lung Diagnostic Supports Physician's Assessment, Prompts Follow-Up Imaging and Defers Unnecessary Biopsy
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #BIAF--Patient case study in which CyPath Lung spared a high-risk patient with a suspicious nodule and elevated risk from an invasive biopsy,.
bioAffinity Technologies Transcript: Status update
Pulmonary nodule detection is rising due to expanded screening, creating clinical challenges. CyPath Lung, a non-invasive sputum test, offers high sensitivity and negative predictive value, aiding risk stratification and reducing unnecessary procedures. Case studies show its value in early cancer detection and patient reassurance.
BioAffinity announces CyPath Lung to be featured at Cleveland Clinic symposium
bioAffinity Technologies (BIAF) announces that its CyPath Lung test will be featured at the invitation-only “Advances in Early Lung Cancer Detection” symposium at the Cleveland Clinic in Cleveland, Oh...
bioAffinity Technologies' CyPath® Lung to Be Featured at Cleveland Clinic Annual “Advances in Early Lung Cancer Detection” Symposium April 16
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #BIAF--CyPath Lung, bioAffinity Technologies' noninvasive test for lung cancer, will be featured at the Cleveland Clinic's annual lung cancer symposium.
BioAffinity’s CyPath Lung Test unit sales surged 146% y/y in Q1
bioAffinity Technologies (BIAF) announced that unit sales for its CyPath Lung diagnostic in the first quarter of 2026 exceeded internal projections and, based on preliminary unaudited data, achieved 1...
bioAffinity Technologies' CyPath® Lung Test Unit Sales Surged 146% Year-Over-Year in Q1 2026
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #CyPathLung--bioAffinity Technologies' CyPath Lung Sales Surged 146% Year-Over-Year in Q1 2026, gaining traction in the U.S. addressable market of $3.58 billion.
bioAffinity Technologies Slides: Investor presentation
bioAffinity Technologies has posted slides in relation to its latest quarterly earnings report, which was published on March 26, 2026.
bioAffinity Technologies to Host Live Virtual Physician Roundtable on Integrating CyPath® Lung into Pulmonary Practice
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #BIAF--bioAffinity Technologies will host a webinar on April 8 with leading pulmonologists who will share their clinical experience with CyPath Lung.
New Case Study: bioAffinity Technologies' CyPath® Lung Provides Actionable Results and Helps Patient Avoid Costly, Invasive Procedures
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #BIAF--bioAffinity Technologies' new patient case study demonstrates the benefit of CyPath Lung in physician decision-making and patient outcome.
bioAffinity Technologies Proxy statement: Proxy Filing
bioAffinity Technologies filed a proxy statement on March 16, 2026, providing details for shareholder voting and corporate governance matters.
bioAffinity Technologies Announces Record 2025 Revenue and Unit Sales for Flagship Lung Cancer Diagnostic CyPath® Lung
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #BIAF--bioAffinity Technologies reports financial results for FY 2025, including record revenue and unit sales for the CyPath Lung test for lung cancer.
bioAffinity Technologies Annual report: Q4 2025
bioAffinity Technologies has published its Q4 2025 annual report on March 13, 2026.
bioAffinity Technologies Earnings release: Q4 2025
bioAffinity Technologies released its Q4 2025 earnings on March 13, 2026, summarizing the period's financial results.
BioAffinity Technologies initiates clinical study for CyPath Lung
BioAffinity Technologies (BIAF) announced initiation of the company’s planned large-scale, longitudinal clinical study for CyPath Lung, its noninvasive diagnostic test for the detection of early-stage...